Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial

Published:2023-10 Issue:10 Volume:10 Page:e653-e662
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Sobieszczyk Magdalena E,Mannheimer Sharon,Paez Carmen A,Yu Chenchen,Gamble Theresa,Theodore Deborah A,Chege Wairimu,Yacovone Margaret,Hanscom Brett,Heptinstall Jack,Seaton Kelly E,Zhang Lily,Miner Maurine D,Eaton Amanda,Weiner Joshua A,Mayer Kenneth,Kalams Spyros,Stephenson Kathryn,Julg Boris,Caskey Marina,Nussenzweig Michel,Gama Lucio,Barouch Dan H,Ackerman Margaret E,Tomaras Georgia D,Huang Yunda,Montefiori David

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference32 articles.

1. Broadly neutralizing antibodies for HIV prevention;Karuna;Annu Rev Med,2020

2. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review;Mahomed;J Infect Dis,2021

3. Broadly neutralizing antibodies for HIV-1 prevention;Walsh;Front Immunol,2021

4. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults;Gaudinski;PLoS Med,2018

5. FcRn: the neonatal Fc receptor comes of age;Roopenian;Nat Rev Immunol,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2;Communications Biology;2024-07-16

2. Is HIV epidemic control by 2030 realistic?;The Lancet HIV;2024-07

3. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial;PLOS Medicine;2024-06-24

4. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives;Clinical Microbiology Reviews;2024-06-13

5. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention;Viruses;2024-06-04